Form 4: Macrogenics Director Edward Hurwitz Reports Stock Transactions
SEC Form 4 Filing
Director Edward Hurwitz reports acquisition and disposal of Macrogenics stock and derivative securities.
Summary
- On May 20, 2025, Edward Hurwitz, a director of Macrogenics Inc., reported transactions involving the company's stock.
- Hurwitz acquired 6,500 shares of common stock through the vesting of restricted stock units (RSUs).
- These RSUs vested on May 20, 2025, one day before the company's annual meeting.
- On May 21, 2025, Hurwitz was granted 3,750 additional RSUs that will vest one year from the grant date or the day prior to the next annual meeting, if earlier.
- Hurwitz also acquired 22,000 stock options with an exercise price of $1.49, vesting in monthly increments starting one month from the grant date, and expiring on May 21, 2035.
- Following these transactions, Hurwitz directly owns 44,074 shares of Macrogenics common stock, 3,750 RSUs, and 22,000 stock options.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock transactions by a company director. The acquisition of shares and options suggests a degree of confidence, but it's not overtly positive or negative.
Positives
- The acquisition of stock options and RSUs by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule of the RSUs and stock options suggests a continued involvement and interest of the director in the company's performance.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's securities. It's common for directors and officers to receive stock options and RSUs as part of their compensation packages, aligning their interests with those of shareholders.
Stakeholder Impact
- The transactions could have a minor positive impact on shareholder sentiment, as they reflect a director's continued investment in the company.
Key Dates
| Date | Description |
|---|---|
| 05/20/2025 | RSUs vested, resulting in the acquisition of 6,500 shares of common stock. |
| 05/21/2025 | Grant date of 3,750 RSUs and 22,000 stock options. |
| 05/21/2035 | Expiration date of the stock options. |
| 05/22/2025 | Date of the Form 4 filing. |
Keywords
Macrogenics, MGNX, Form 4, Insider Trading, Edward Hurwitz, Stock Options, Restricted Stock Units, Director, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.